Skip to main content
Explore URMC
menu

Melanoma: Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

Research Question:
What are the good and bad effects of using ipilimumab in combination with nivolumab compared to the usual approach of using ipilimumab alone?

Basic Study Information

Purpose:
If you decide to participate in this research study, you will be randomly assigned to one of the treatment groups. This is done by chance, for every patient assigned to group 1 (ipilimumab alone) the computer will assign 3 patients to group 2 (ipilimumab and nivolumab). If you are assigned to group 1 (ipilimumab alone), you will receive the study drug for 12 weeks. If you are assigned to group 2 (ipilimumab and nivolumab) you will receive both ipilimumab and nivolumab for 12 weeks and then nivolumab alone for as long as your cancer does not get worse, the side effects are tolerable, and you agree to stay on study.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03033576?term=s1616&rank=1
Study Reference #: CMEL17134

Lead Researcher (Principal Investigator)

Lead Researcher: Deepak Sahasrabudhe, MD

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351
Email: Ayesha_Khan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Melanoma

Return to Search